Esomeprazole - Daewon Pharmaceutical
Alternative Names: DW-1903; DW1903-R2Latest Information Update: 04 Aug 2023
At a glance
- Originator Daewon Pharmaceutical
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antibacterials; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Gastritis
Most Recent Events
- 04 Aug 2023 Chemical structure information added
- 22 Mar 2023 Pharmacodynamics and adverse events data from a phase I trial in Gastritis (In volunteers) presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2023)
- 25 Nov 2020 Phase-III clinical trials in Gastritis in South Korea (PO) (NCT05163756)